<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of nontuberculous mycobacteria (excluding MAC) in patients with HIV
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of nontuberculous mycobacteria (excluding MAC) in patients with HIV
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of nontuberculous mycobacteria (excluding MAC) in patients with HIV
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Matthew R Leibowitz, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Judith S Currier, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rajesh T Gandhi, MD, FIDSA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 15, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of disease due to nontuberculous mycobacteria (NTM) in patients with HIV is caused by
         <em>
          Mycobacterium avium
         </em>
         complex (MAC); however, other NTM are important pathogens. Infection with NTM other than MAC can be disseminated or localized, and similar to MAC, the risk of disease increases with progressive immunodeficiency. The greatest risk occurs when the CD4 count decreases below 50 cells/microL. Although the numbers of NTM cases have declined dramatically in people treated with antiretroviral therapy (ART), it is important to consider these pathogens in people with HIV who are not receiving ART and those who present with symptoms or signs of an opportunistic infection.
        </p>
        <p>
         This topic will review the clinical manifestations and treatment of the most commonly isolated NTM species in people with HIV. Topic reviews that discuss MAC and the microbiology, pathogenesis, epidemiology, and clinical manifestations of NTM in people without HIV are found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5343.html" rel="external">
          "Microbiology of nontuberculous mycobacteria"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3755.html" rel="external">
          "Mycobacterium avium complex (MAC) infections in persons with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5342.html" rel="external">
          "Overview of nontuberculous mycobacterial infections"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PRINCIPLES OF DIAGNOSIS AND THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnosis and therapy of NTM in people with HIV require a thorough clinical assessment combined with culture data and appropriately directed empiric therapy.
        </p>
        <p>
         When NTM are isolated from a usually sterile site (eg, blood, bone marrow, lymph nodes, synovial fluid), the diagnosis of true disease is generally straightforward. However, when NTM are isolated from non-sterile sites, such as sputum or bronchoalveolar lavage fluid, the diagnosis is less definitive, especially when the colony numbers are low or the isolate is present in only one cultured specimen. A diagnosis of infection then depends upon other clinical findings, radiographic findings, and the presence or absence of other pathogens. Organisms considered in other circumstances to be commensals can be opportunistic pathogens in people with advanced HIV disease and immunodeficiency [
         <a href="#rid1">
          1
         </a>
         ]. A case series from Spain identified 26 people with HIV between 1998 and 2005 with NTM isolates from sputum [
         <a href="#rid2">
          2
         </a>
         ]. Using clinical criteria to establish a diagnosis of colonization versus infection, the factors associated with disease were CD4 counts &lt;50 cells/microL, weight loss, hemoglobin below 11g/dL, duration of symptoms longer than a month, AFB smear positive sputum, and repeated positive NTM cultures.
        </p>
        <p>
         It is important to remember that experience with NTM other than MAC and
         <em>
          Mycobacterium kansasii
         </em>
         is limited, and treatment decisions must be individualized. Further reports of infection with new NTM strains characterized by their unique 16S ribosomal RNA continue, adding to a growing list of rare pathogens for which diagnosis and treatment are unclear [
         <a href="#rid3">
          3
         </a>
         ]. In the Spanish study noted above [
         <a href="#rid2">
          2
         </a>
         ], MAC and
         <em>
          M. kansasii
         </em>
         caused all disease, whereas other NTM were considered to be colonizers.
        </p>
        <p>
         Species identification of NTM is usually made through traditional biochemical testing of isolates; thus, results are often not available for weeks. However, newer molecular testing methods of clinical specimens, using direct amplification of nucleic acid probes (eg, Gen-Probe and AccuProbe) to rapidly identify
         <em>
          Mycobacterium tuberculosis
         </em>
         ,
         <em>
          M. kansasii
         </em>
         , and MAC, can produce results in hours. In addition, newer line probe assays (LPAs) have enabled species- and subspecies-level identification of some species of NTM while also allowing for the detection of antibiotic resistance for aminoglycosides and macrolides by the identification of specific gene mutations [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         The recommendations of the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) for treatment of NTM [
         <a href="#rid5">
          5
         </a>
         ] and the consensus management recommendations for less common NTM pulmonary infections [
         <a href="#rid6">
          6
         </a>
         ] serve as useful guides to the treatment of NTM. Although these guidelines focus on patients without HIV, most of the recommendations can also be applied to people with HIV. However, there are significant drug interactions with rifamycins and the preferred antiretroviral agents used for HIV treatment, and this may impact antiretroviral therapy regimen selection. (See
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129782.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naive persons with HIV-1: Patients with comorbid conditions", section on 'Patients with opportunistic infections'
         </a>
         .)
        </p>
        <p>
         In patients initiating ART, an immune reconstitution inflammatory syndrome (IRIS; the paradoxical worsening of pre-existing infectious processes after the start of combination antiretroviral therapy) has been frequently described among people with HIV and known or previously undiagnosed mycobacterial infection, both tuberculous and nontuberculous. The vast majority of nontuberculous mycobacterial infections resulting in IRIS are due to MAC, but cases of IRIS related to infection with a variety of NTM other than MAC have been reported [
         <a href="#rid7">
          7-10
         </a>
         ]. The immunobiology, pathogenesis, diagnosis, and treatment of IRIS related to mycobacterial infection are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">
          "Immune reconstitution inflammatory syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          MYCOBACTERIUM KANSASII
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          M. kansasii
         </em>
         is the most frequently isolated NTM after MAC [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Epidemiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The environmental source for the organism is not certain, but person-to-person transmission does not occur. Tap water is thought to be the most likely environmental source of exposure [
         <a href="#rid5">
          5
         </a>
         ]. Areas of greatest endemicity in the United States include Louisiana, Illinois, Texas, and Florida [
         <a href="#rid12">
          12
         </a>
         ]. The incidence of isolation of this emerging pathogen is increasing.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         During the period 1970 to 1990,
         <em>
          M. kansasii
         </em>
         became the most frequently isolated mycobacterial species overall in a Nebraska Veteran's Affairs hospital [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Case series of
         <em>
          M. kansasii
         </em>
         infection have been reported from various regions worldwide, including Florida [
         <a href="#rid14">
          14
         </a>
         ] and Spain [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Clinical manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations are most similar to those of
         <em>
          M. tuberculosis
         </em>
         , although
         <em>
          M. kansasii
         </em>
         is a less virulent pathogen [
         <a href="#rid1">
          1
         </a>
         ]. Typical symptoms include fever, night sweats, weight loss, cough with sputum, dyspnea, and weakness. Pulmonary disease consists of infiltrates on chest radiograph with isolation of the organism from at least two respiratory specimens. The presentation of
         <em>
          M. kansasii
         </em>
         pulmonary infection usually does not differ in those who do or do not have HIV, but the incidence of disseminated infection with this organism is higher in people with HIV. Disseminated disease can be diagnosed by isolation of
         <em>
          M. kansasii
         </em>
         from sites other than the respiratory system, hilar lymph nodes, or skin.
        </p>
        <p>
         In the series of 46 patients from Florida, the median CD4 count in people with HIV and
         <em>
          M. kansasii
         </em>
         infection was 34/microL [
         <a href="#rid14">
          14
         </a>
         ]. Forty-two patients (91 percent) had pulmonary infection; six of these cases also had disseminated disease. Only four (8 percent) of the patients had extrapulmonary disease without accompanying pulmonary involvement. The extrapulmonary sites included adenitis, bacteremia, osteomyelitis, and pericarditis.
        </p>
        <p>
         A population-based survey from California during 1992 to 1996 identified 270 infections with
         <em>
          M. kansasii
         </em>
         , and found that 69.3 percent of these cases were among individuals with HIV [
         <a href="#rid16">
          16
         </a>
         ]. People with HIV infection were more likely to have mycobacteremia (9.6 percent versus 0 percent) and smear-positive respiratory specimens (41.7 percent versus 20.7 percent). Hospitalization for treatment was more common in the group with HIV.
        </p>
        <p>
         A case-control study from Spain compared the clinical presentations of
         <em>
          M. kansasii
         </em>
         and
         <em>
          M. tuberculosis
         </em>
         in people with HIV and found that presenting symptoms and rates of dissemination were similar, but patients with
         <em>
          M. kansasii
         </em>
         presented with lower CD4 cell counts (median of 20 versus 90 for
         <em>
          M. tuberculosis
         </em>
         ) [
         <a href="#rid17">
          17
         </a>
         ]. The survival was worse for
         <em>
          M. kansasii
         </em>
         -infected patients, and central nervous system (CNS) disease was seen exclusively with
         <em>
          M. tuberculosis
         </em>
         infection.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Radiography
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common radiographic findings included interstitial and lobar infiltrates [
         <a href="#rid14">
          14
         </a>
         ]. Cavitation, nodules, hilar adenopathy, and pleural effusion occurred less frequently. There is no clear predominance of upper or lower lobe involvement noted in the literature, and the radiographic appearance does not reliably distinguish
         <em>
          M. kansasii
         </em>
         from
         <em>
          M. tuberculosis
         </em>
         [
         <a href="#rid18">
          18
         </a>
         ]. Anecdotal reports of unusual presentations, such as cranial osteomyelitis, can be found [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of
         <em>
          M. kansasii
         </em>
         in patients with HIV often begins with empiric therapy for
         <em>
          M. tuberculosis
         </em>
         after acid-fast organisms are identified upon staining of respiratory specimens. After identification of
         <em>
          M. kansasii
         </em>
         is confirmed by biochemical testing or nucleic acid probe, therapy can be modified. We agree with the 2020 American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) NTM guidance that supports the use of susceptibility-based testing for
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         to guide treatment decisions. In patients with rifampin-susceptible
         <em>
          M. kansasii
         </em>
         pulmonary disease, a regimen of rifampicin,
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         , and either
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         or a macrolide is recommended. Fluoroquinolones should be reserved for patients with rifampicin resistance or intolerance to one of the other first-line agents. More detailed information on the treatment of
         <em>
          M. Kansasii
         </em>
         infection is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/107702.html" rel="external">
          "Treatment of lung infection with
          <i>
           Mycobacterium kansasii
          </i>
          and other less common nontuberculous mycobacteria in adults", section on 'M. kansasii'
         </a>
         .)
        </p>
        <p>
         In people with HIV, treatment of
         <em>
          M. kansasii
         </em>
         conferred a clear survival benefit in various case series, suggesting that this organism should be considered a pathogen in all cases, unless there is absolutely no clinical evidence to support the diagnosis of
         <em>
          M. kansasii
         </em>
         disease [
         <a href="#rid20">
          20,21
         </a>
         ]. In one retrospective report, treatment with a regimen including
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         was associated with prolonged survival in both the pre- and post-combination antiretroviral therapy (ART) eras [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Prognosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a series from California, among 127 people with HIV infection and pulmonary
         <em>
          M. kansasii
         </em>
         infection, 53 percent died [
         <a href="#rid21">
          21
         </a>
         ]. Predictors of survival included higher CD4 cell count, ART, negative smear microscopy, and adequate treatment for
         <em>
          M. kansasii
         </em>
         [
         <a href="#rid21">
          21
         </a>
         ]. In the New Orleans series [
         <a href="#rid22">
          22
         </a>
         ], median survival in the combination ART era was 10.5 months when pulmonary disease was treated and 4.5 months when disease was not treated, indicating a poor prognosis in this severely immunocompromised population.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          MYCOBACTERIUM XENOPI
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Mycobacterium xenopi
         </em>
         can be isolated from water, especially hot water sources, and is often considered a commensal. Reports of the endemicity of this organism vary. In a representative series of 28 patients from Toronto with both HIV and
         <em>
          M. xenopi
         </em>
         infection, 19 of 24 patients with measured CD4 counts had &lt;100 cells/microL [
         <a href="#rid23">
          23
         </a>
         ]. Only seven patients (25 percent) were thought to have clinically significant disease [
         <a href="#rid24">
          24
         </a>
         ]. Three other patients had pulmonary disease with repeated isolation of
         <em>
          M. xenopi
         </em>
         , but other potential pathogens were also identified. In a study from Buffalo, 23 of 35 patients (66 percent) with AIDS and pulmonary NTM other than MAC and
         <em>
          M. kansasii
         </em>
         had isolates of
         <em>
          M. xenopi
         </em>
         [
         <a href="#rid25">
          25
         </a>
         ]. Cavitary disease was rare, and interstitial and nodular lung disease were more common. A subsequent report from the Netherlands found that 25 of 49 patients (51 percent) with positive cultures for
         <em>
          M.
         </em>
         xenopi met diagnostic criteria for infection [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         The isolates were from lower respiratory specimens (sputum, bronchoalveolar lavage fluid, or lung biopsy) in 24 patients (86 percent) in the Ottawa study [
         <a href="#rid23">
          23
         </a>
         ]. Three patients had bacteremia and a prolonged febrile illness with wasting, similar to disseminated MAC. Two had respiratory isolation of
         <em>
          M. xenopi
         </em>
         and
         <em>
          Pneumocystis carinii
         </em>
         simultaneously. Three patients had
         <em>
          M. xenopi
         </em>
         isolated from extrapulmonary sites: one each from inguinal lymph node, diarrheal stool, and urine.
        </p>
        <p>
         Four of the patients thought to have clinical disease were treated, and one appeared to respond [
         <a href="#rid23">
          23
         </a>
         ]. Sixteen patients died a median of six months after the isolation of
         <em>
          M. xenopi
         </em>
         , although none of the deaths were directly attributable to the organism. In a retrospective analysis, treated patients survived longer than untreated patients [
         <a href="#rid25">
          25
         </a>
         ]. The distinction between colonization and disease may be difficult upon isolation of
         <em>
          M. xenopi
         </em>
         .
        </p>
        <p>
         Case reports describing vertebral osteomyelitis and discitis have been published [
         <a href="#rid26">
          26-28
         </a>
         ]. Few cases of
         <em>
          M. xenopi
         </em>
         spontaneous vertebral infection have been reported, but the disease course seems similar to that caused by
         <em>
          M. tuberculosis
         </em>
         .
        </p>
        <p>
         If
         <em>
          M. xenopi
         </em>
         is isolated as a single pathogen in a symptomatic patient with HIV, treatment may prolong survival. In vitro susceptibility of
         <em>
          M. xenopi
         </em>
         to
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         is often reduced, but response to therapy does not always correlate with susceptibility data. The 2020 treatment guidelines for NTM acknowledged that there is insufficient evidence to make a recommendation about the use of susceptibility testing for
         <em>
          M. xenopi
         </em>
         and suggest using a daily regimen that includes at least three drugs; rifampicin, ethambutol, and either a macrolide or quinolone (eg.
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         [
         <a href="#rid5">
          5
         </a>
         ]). Parenteral
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         can be added in the presence of severe bronchiectatic disease. (See
         <a class="medical medical_review" href="/z/d/html/107702.html" rel="external">
          "Treatment of lung infection with
          <i>
           Mycobacterium kansasii
          </i>
          and other less common nontuberculous mycobacteria in adults", section on 'M. xenopi'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          MYCOBACTERIUM HAEMOPHILUM
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Mycobacterium haemophilum
         </em>
         disease most commonly presents in people with HIV as painful, erythematous, ulcerating skin nodules [
         <a href="#rid1">
          1
         </a>
         ]. Patients with tenosynovitis, arthritis, and osteomyelitis have also been reported. Similar to
         <em>
          Mycobacterium marinum
         </em>
         and
         <em>
          Mycobacterium ulcerans
         </em>
         , the organism grows best at 30 to 32°C, explaining its tendency to cause skin and joint disease [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         <em>
          M. haemophilum
         </em>
         has been isolated from the blood, bone marrow, sputum, and bronchoalveolar lavage fluid of people with HIV. Symptoms suggestive of disseminated disease frequently are present. Cases of central nervous system infection has also been described [
         <a href="#rid30">
          30,31
         </a>
         ]. Although cough is a common symptom, this organism has not definitively been confirmed to be a pulmonary pathogen.
        </p>
        <p>
         <em>
          M. haemophilum
         </em>
         is more difficult than other NTM to isolate since it requires ferric ions (available in chocolate agar, supplemented media, and often in blood culture systems such as BACTEC or lysis centrifugation). The limited clinical experience in treating patients with
         <em>
          M. haemophilum
         </em>
         disease and the variable relationship between in vitro susceptibility data and in vivo activity also makes the choice of therapy problematic. Successful use of combinations of three or four drugs including
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         , rifamycins, fluoroquinolones,
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         , and
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         has been reported [
         <a href="#rid32">
          32-36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          MYCOBACTERIUM SIMIAE
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          M. simiae
         </em>
         was originally isolated from rhesus monkeys and later from tap water. Infection with this organism may present in a fashion similar to disseminated MAC, with fever, night sweats, weight loss, and adenopathy, although its pathogenicity is not entirely clear [
         <a href="#rid1">
          1
         </a>
         ]. Often thought to be a commensal in respiratory isolates, it has been described to cause pulmonary infection, disseminated disease with isolation from blood, osteomyelitis, and renal infection in people with AIDS [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p>
         <em>
          M. simiae
         </em>
         often is resistant to
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         , and aminoglycosides in vitro.
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          Trimethoprim-sulfamethoxazole
         </a>
         , quinolones, and
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         may be effective, but experience in treating this infection is limited [
         <a href="#rid38">
          38-40
         </a>
         ]. Overall prognosis was poor unless patients responded to both antiretroviral and antimycobacterial therapy [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          MYCOBACTERIUM MALMOENSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Mycobacterium malmoense
         </em>
         has been isolated from water and soil, and is a rarely isolated pathogen in the United States [
         <a href="#rid5">
          5
         </a>
         ]. The clinical presentation is similar to pulmonary infection with
         <em>
          M. tuberculosis
         </em>
         , but soft tissue infections, tenosynovitis, adenitis in children, and disseminated infection has been described [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Although in vitro data suggested resistance to
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         and
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         , treatment with these agents for 18 to 24 months has been successful in people without HIV.
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          Clarithromycin
         </a>
         has also been shown to be active in vitro [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          MYCOBACTERIUM FORTUITUM AND MYCOBACTERIUM CHELONAE
         </span>
         <span class="headingEndMark">
          —
         </span>
         These rapidly growing mycobacteria are environmental organisms found worldwide and may grow in culture in less than one week. They are a cause of cutaneous infection, especially following trauma or surgery [
         <a href="#rid1">
          1
         </a>
         ]. In immunocompromised patients, reports of disease include disseminated disease with pustular and nodular cutaneous lesions, localized pulmonary disease with adenopathy, multifocal osteomyelitis, and lymphadenitis. A case series published in 2001 describes patients who predominantly presented with cervical lymphadenitis and fever and received other treatments before
         <em>
          Mycobacterium fortuitum
         </em>
         infection was diagnosed. The morphologic appearance of the sometimes irregularly staining mycobacteria resulted in misdiagnosis of Nocardia in 7 of 11 patients, highlighting the difficulty in diagnosing this infection [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         Antimicrobials used with success include intravenous
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         ,
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9223" href="/z/d/drug information/9223.html" rel="external">
          cefoxitin
         </a>
         , and oral
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         , and
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         [
         <a href="#rid5">
          5,43
         </a>
         ]. The optimal duration of therapy is not defined, but treatment for a minimum of 6 to 12 months should be considered.
        </p>
        <p>
         A nosocomial pseudo-outbreak of
         <em>
          M. fortuitum
         </em>
         , linked to a contaminated ice machine on an HIV inpatient ward, was reported in Baltimore [
         <a href="#rid44">
          44
         </a>
         ]. Of 47 patients with at least one sputum specimen positive for
         <em>
          M. fortuitum
         </em>
         , only one had any signs of progressive pulmonary infection over six months of follow-up.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          MYCOBACTERIUM GENAVENSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          M. genavense
         </em>
         is a mycobacterial species that was discovered when disseminated infection with an unidentified mycobacterium was reported in 18 patients in Switzerland in 1990 [
         <a href="#rid45">
          45
         </a>
         ]. Cases have since been reported worldwide, but almost exclusively in people with AIDS and CD4 counts &lt;100 cells/microL or other immunocompromising conditions, such as solid organ transplantation [
         <a href="#rid1">
          1,46,47
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         - The clinical presentation of
         <em>
          M. genavense
         </em>
         infection can be similar to those with disseminated
         <em>
          Mycobacterium avium
         </em>
         complex (MAC) infection, since fevers, weight loss, and hepatosplenomegaly are common. In a comparison of 12 patients with HIV and disseminated
         <em>
          M. genavense
         </em>
         and 24 patients with HIV and disseminated MAC infection, the illness and survival times after diagnosis were similar, but patients with MAC were less likely to have abdominal pain [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         <em>
          M. genavense
         </em>
         infection can be associated with massive adenopathy and organomegaly, especially splenomegaly, sometimes with splenic abscess. In one report, a syndrome of retractile mesenteritis was described, which was associated with duodenal wall thickening, central mesenteric mass, and thrombotic events [
         <a href="#rid49">
          49
         </a>
         ]. In a case series that described the radiographic finding associated with
         <em>
          M. genavense,
         </em>
         mesenteric adenopathy was common. In addition, small bowel thickening and hepatic nodules were noted on computed tomography (CT) imaging [
         <a href="#rid50">
          50
         </a>
         ]. Although pulmonary infection has not been clearly demonstrated, one patient had nodular infiltrates and a small upper lobe cavity on chest CT. In a systematic review of 223 mostly European patients (77 percent with HIV), pulmonary symptoms and radiographic changes were seen in 12.6 and 9.5 percent of patients; gastrointestinal involvement was common [
         <a href="#rid51">
          51
         </a>
         ]. Cases of
         <em>
          M. genavense
         </em>
         infection of the brain mimicking a brain tumor have also been described [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         In the study that compared patients with HIV who had
         <em>
          M. genavense
         </em>
         to those with MAC, stool specimens tended to be smear-positive for
         <em>
          M. genavense
         </em>
         , but the organism was less likely to grow in stool culture compared with MAC (15 versus 71 percent) [
         <a href="#rid48">
          48
         </a>
         ]. By contrast, bone marrow and liver biopsy specimens grew
         <em>
          M. genavense
         </em>
         more readily; the yield was maximized by using acidic liquid medium and additives and avoiding pretreatment.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         - Treatment regimens usually include macrolides, rifamycins,
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         , and quinolones.
         <em>
          M. genavense
         </em>
         shows resistance to
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         in vitro [
         <a href="#rid48">
          48
         </a>
         ]. A French case series described successful treatment with
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         , ethambutol,
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         , and quinolones in various combinations for durations of 12 to 15 months [
         <a href="#rid47">
          47
         </a>
         ]. In the systematic review of 223 cases mentioned above [
         <a href="#rid51">
          51
         </a>
         ], most patients were treated with macrolides, rifamycins and ethambutol. Treatment with a macrolide was associated with improved outcome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impact of ART and IRIS
         </strong>
         - ART is an important component of therapy and is associated with improved mortality outcomes. In a systematic review of 223 mostly European cases from 1992 to 2021 (77 percent with HIV), 94 patients died in the pre-combination antiretroviral therapy (cART) era (89.9 percent mortality after 24 months) and 77 in the cART era (39.3 percent five-year mortality) [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         IRIS can occur after the initiation of ART in this patient population and can be difficult to distinguish from poor response to NTM therapy. In a French case series of 19 patients who initiated ART after the diagnosi
         <em>
          s of M. genavense
         </em>
         infection, five (25 percent) developed an immune reconstitution syndrome [
         <a href="#rid47">
          47
         </a>
         ]. A case series of three patients with advanced HIV
         <em>
          and M. genavense
         </em>
         infection demonstrated the significant clinical challenge to distinguish poor response to antimycobacterial therapy from immune reconstitution inflammatory syndrome (IRIS) requiring anti-inflammatory therapy [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          MYCOBACTERIUM SZULGAI
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Mycobacterium szulgai
         </em>
         can be found in water sources and is usually associated with pulmonary disease in a presentation similar to that of
         <em>
          M. tuberculosis
         </em>
         . Extrapulmonary presentations have been described in people with HIV infection, and include cutaneous disease, osteomyelitis [
         <a href="#rid53">
          53
         </a>
         ], and septic arthritis [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         Pulmonary disease has been successfully treated with various three- and four-drug regimens including macrolides and quinolones for a duration of 12 months with negative sputum cultures [
         <a href="#rid5">
          5
         </a>
         ]. Extrapulmonary disease has been successfully treated with combinations including
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         , and
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         for 12 months [
         <a href="#rid53">
          53,54
         </a>
         ]. A case of pulmonary disease was reported with multidrug resistance to
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , ethambutol, and
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         [
         <a href="#rid55">
          55
         </a>
         ]. After susceptibility results were available, the patient responded well to treatment with clarithromycin,
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         , ciprofloxacin, and
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         .
        </p>
        <p class="headingAnchor" id="H3651619453">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111612.html" rel="external">
          "Society guideline links: Opportunistic infections in adults with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2821423">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Introduction
         </strong>
         - Although the majority of disease due to nontuberculous mycobacteria (NTM) in people with HIV is caused by
         <em>
          Mycobacterium avium
         </em>
         complex (MAC), other NTM are important pathogens as well. The risk of disease from NTM increases with progressive immunodeficiency, with the greatest risk experienced as the CD4 cell count decreases below 50 cells/microL. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Principles of diagnosis and therapy
         </strong>
         - When NTM are isolated from a sterile site (eg, blood), the diagnosis of true disease is generally straightforward. However, when NTM are isolated from non-sterile sites, such as sputum, the diagnosis is less definitive. In the latter situation, a diagnosis of true NTM infection depends upon other clinical findings, radiographic findings, and the presence or absence of other potential pathogens. (See
         <a class="local">
          'Principles of diagnosis and therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mycobacterium kansasii
         </strong>
         -
         <em>
          Mycobacterium kansasii
         </em>
         is the most frequently isolated NTM after MAC. The clinical manifestations are most similar to those of tuberculosis, although
         <em>
          Mycobacterium kansasii
         </em>
         is a less virulent pathogen. Typical symptoms include fever, night sweats, weight loss, cough with sputum, dyspnea, and weakness. (See
         <a class="local">
          'Mycobacterium kansasii'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mycobacterium xenopi
         </strong>
         -
         <em>
          Mycobacterium xenopi
         </em>
         can cause fevers, wasting and pulmonary infiltrates, similar to disseminated
         <em>
          M. avium
         </em>
         complex. (See
         <a class="local">
          'Mycobacterium xenopi'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mycobacterium haemophilum
         </strong>
         -
         <em>
          Mycobacterium haemophilum
         </em>
         disease most commonly presents as painful, erythematous, ulcerating skin nodules. Patients with tenosynovitis, arthritis, and osteomyelitis have also been reported. (See
         <a class="local">
          'Mycobacterium haemophilum'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mycobacterium fortuitum and mycobacterium chelonae
         </strong>
         - The rapidly growing mycobacteria,
         <em>
          Mycobacterium fortuitum
         </em>
         and
         <em>
          Mycobacterium chelonae
         </em>
         , can cause disseminated disease with pustular and nodular cutaneous lesions, localized pulmonary disease with adenopathy, multifocal osteomyelitis, and lymphadenitis. (See
         <a class="local">
          'Mycobacterium fortuitum and mycobacterium chelonae'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mycobacterium genavense
         </strong>
         -
         <em>
          Mycobacterium genavense
         </em>
         infection has been associated with massive adenopathy and organomegaly. (See
         <a class="local">
          'Mycobacterium genavense'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mycobacterium szulgai
         </strong>
         -
         <em>
          Mycobacterium szulgai
         </em>
         has been associated with pulmonary disease, cutaneous lesions, osteomyelitis, and septic arthritis. (See
         <a class="local">
          'Mycobacterium szulgai'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3368777140">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Benator DA, Gordin FM. Nontuberculous mycobacteria in patients with human immunodeficiency virus infection. Semin Respir Infect 1996; 11:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvarez-Uria G, Falcó V, Martín-Casabona N, et al. Non-tuberculous mycobacteria in the sputum of HIV-infected patients: infection or colonization? Int J STD AIDS 2009; 20:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richter E, Rüsch-Gerdes S, Niemann S, et al. Detection, identification, and treatment of a novel, non-cultivable Mycobacterium species in an HIV patient. AIDS 2000; 14:1667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huh HJ, Kim SY, Shim HJ, et al. GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance. J Clin Microbiol 2019; 57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daley CL, Iaccarino JM, Lange C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis 2020; 71:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lange C, Böttger EC, Cambau E, et al. Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infect Dis 2022; 22:e178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips P, Bonner S, Gataric N, et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis 2005; 41:1483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips DR, Krishnan H, Watson J. First UK report of successful treatment of Mycobacterium simiae and immune reconstitution inflammatory syndrome in an HIV-seropositive patient. Sex Transm Infect 2008; 84:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manion M, Lynn N, Pei L, et al. To Induce Immune Reconstitution Inflammatory Syndrome or Suppress It: The Spectrum of Mycobacterium genavense in the Antiretroviral Era. Clin Infect Dis 2021; 72:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horsburgh CR Jr, Selik RM. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 1989; 139:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Good RC, Snider DE Jr. Isolation of nontuberculous mycobacteria in the United States, 1980. J Infect Dis 1982; 146:829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bittner MJ, Horowitz EA, Safranek TJ, Preheim LC. Emergence of Mycobacterium kansasii as the leading mycobacterial pathogen isolated over a 20-year period at a midwestern Veterans Affairs hospital. Clin Infect Dis 1996; 22:1109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campo RE, Campo CE. Mycobacterium kansasii disease in patients infected with human immunodeficiency virus. Clin Infect Dis 1997; 24:1233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pintado V, Gómez-Mampaso E, Martín-Dávila P, et al. Mycobacterium kansasii infection in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 1999; 18:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloch KC, Zwerling L, Pletcher MJ, et al. Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med 1998; 129:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canueto-Quintero J, Caballero-Granado FJ, Herrero-Romero M, et al. Epidemiological, clinical, and prognostic differences between the diseases caused by Mycobacterium kansasii and Mycobacterium tuberculosis in patients infected with human immunodeficiency virus: a multicenter study. Clin Infect Dis 2003; 37:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans AJ, Crisp AJ, Hubbard RB, et al. Pulmonary Mycobacterium kansasii infection: comparison of radiological appearances with pulmonary tuberculosis. Thorax 1996; 51:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capdevila O, Zurita A, Domingo E, et al. Multiple cranial osteolytic lesions due to Mycobacterium kansasii in a patient with AIDS. Scand J Infect Dis 1998; 30:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marras TK, Daley CL. A systematic review of the clinical significance of pulmonary Mycobacterium kansasii isolates in HIV infection. J Acquir Immune Defic Syndr 2004; 36:883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marras TK, Morris A, Gonzalez LC, Daley CL. Mortality prediction in pulmonary Mycobacterium kansasii infection and human immunodeficiency virus. Am J Respir Crit Care Med 2004; 170:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tompkins JC, Witzig RS. Mycobacterium kansasii in HIV patients: clarithromycin and antiretroviral effects. Int J Tuberc Lung Dis 2007; 11:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           el-Helou P, Rachlis A, Fong I, et al. Mycobacterium xenopi infection in patients with human immunodeficiency virus infection. Clin Infect Dis 1997; 25:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 1997; 156:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Solh AA, Nopper J, Abdul-Khoudoud MR, et al. Clinical and radiographic manifestations of uncommon pulmonary nontuberculous mycobacterial disease in AIDS patients. Chest 1998; 114:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Ingen J, Boeree MJ, de Lange WC, et al. Mycobacterium xenopi clinical relevance and determinants, the Netherlands. Emerg Infect Dis 2008; 14:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meybeck A, Fortin C, Abgrall S, et al. Spondylitis due to Mycobacterium xenopi in a human immunodeficiency virus type 1-infected patient: case report and review of the literature. J Clin Microbiol 2005; 43:1465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobottke R, Zarghooni K, Seifert H, et al. Spondylodiscitis caused by Mycobacterium xenopi. Arch Orthop Trauma Surg 2008; 128:1047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saubolle MA, Kiehn TE, White MH, et al. Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans. Clin Microbiol Rev 1996; 9:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buppajarntham A, Apisarnthanarak A, Rutjanawech S, Khawcharoenporn T. Central nervous system infection due to Mycobacterium haemophilum in a patient with acquired immunodeficiency syndrome. Int J STD AIDS 2015; 26:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kon S, Franco-Paredes C, Hawkins KL. Intramedullary spinal cord lesions in an immunocompromised host due to Mycobacterium haemophilum. IDCases 2020; 19:e00674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dever LL, Martin JW, Seaworth B, Jorgensen JH. Varied presentations and responses to treatment of infections caused by Mycobacterium haemophilum in patients with AIDS. Clin Infect Dis 1992; 14:1195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Straus WL, Ostroff SM, Jernigan DB, et al. Clinical and epidemiologic characteristics of Mycobacterium haemophilum, an emerging pathogen in immunocompromised patients. Ann Intern Med 1994; 120:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodworth MH, Marquez C, Chambers H, Luetkemeyer A. Disabling Dactylitis and Tenosynovitis Due to Mycobacterium haemophilum in a Patient With Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome. Open Forum Infect Dis 2017; 4:ofx165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelley CF, Armstrong WS, Eaton ME. Disseminated Mycobacterium haemophilum infection. Lancet Infect Dis 2011; 11:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nookeu P, Angkasekwinai N, Foongladda S, Phoompoung P. Clinical Characteristics and Treatment Outcomes for Patients Infected with Mycobacterium haemophilum. Emerg Infect Dis 2019; 25:1648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huminer D, Dux S, Samra Z, et al. Mycobacterium simiae infection in Israeli patients with AIDS. Clin Infect Dis 1993; 17:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Abdely HM, Revankar SG, Graybill JR. Disseminated Mycobacterium simiae infection in patients with AIDS. J Infect 2000; 41:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barzilai A, Rubinovich B, Blank-Porat D, et al. Successful treatment of disseminated Mycobacterium simiae infection in AIDS patients. Scand J Infect Dis 1998; 30:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashok A, Hoy J, Spelman D, et al. Successful treatment of disseminated Mycobacterium simiae infection in a patient with advanced HIV. AIDS 2021; 35:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fakih M, Chapalamadugu S, Ricart A, et al. Mycobacterium malmoense bacteremia in two AIDS patients. J Clin Microbiol 1996; 34:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MB, Schnadig VJ, Boyars MC, Woods GL. Clinical and pathologic features of Mycobacterium fortuitum infections. An emerging pathogen in patients with AIDS. Am J Clin Pathol 2001; 116:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace RJ Jr, Tanner D, Brennan PJ, Brown BA. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 1993; 119:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gebo KA, Srinivasan A, Perl TM, et al. Pseudo-outbreak of Mycobacterium fortuitum on a Human Immunodeficiency Virus Ward: transient respiratory tract colonization from a contaminated ice machine. Clin Infect Dis 2002; 35:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirschel B, Chang HR, Mach N, et al. Fatal infection with a novel, unidentified mycobacterium in a man with the acquired immunodeficiency syndrome. N Engl J Med 1990; 323:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tortoli E, Brunello F, Cagni AE, et al. Mycobacterium genavense in AIDS patients, report of 24 cases in Italy and review of the literature. Eur J Epidemiol 1998; 14:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charles P, Lortholary O, Dechartres A, et al. Mycobacterium genavense infections: a retrospective multicenter study in France, 1996-2007. Medicine (Baltimore) 2011; 90:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomsen VO, Dragsted UB, Bauer J, et al. Disseminated infection with Mycobacterium genavense: a challenge to physicians and mycobacteriologists. J Clin Microbiol 1999; 37:3901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borde JP, Offensperger WB, Kern WV, Wagner D. Mycobacterium genavense specific mesenteritic syndrome in HIV-infected patients: a new entity of retractile mesenteritis? AIDS 2013; 27:2819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monill JM, Franquet T, Sambeat MA, et al. Mycobacterium genavense infection in AIDS: imaging findings in eight patients. Eur Radiol 2001; 11:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wetzstein N, Kessel J, Bingold TM, et al. High overall mortality of Mycobacterium genavense infections and impact of antimycobacterial therapy: Systematic review and individual patient data meta-analysis. J Infect 2022; 84:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toussi A, Goodarzi A, Kulubya E, et al. Mycobacterium Genavense Granuloma Mimicking a Brain Tumor: A Case Report. Cureus 2017; 9:e1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tappe D, Langmann P, Zilly M, et al. Osteomyelitis and skin ulcers caused by Mycobacterium szulgai in an AIDS patient. Scand J Infect Dis 2004; 36:883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hakawi AM, Alrajhi AA. Septic arthritis due to Mycobacterium szulgai in a patient with human immunodeficiency virus: case report. Scand J Infect Dis 2005; 37:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang-Birken SL, Prichard JG. Mycobacterium szulgai in a patient with advanced acquired immunodeficiency syndrome: an unusual pathogen with unusual multidrug resistance. Pharmacotherapy 2006; 26:1646.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3705 Version 27.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8976582" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Nontuberculous mycobacteria in patients with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19255269" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Non-tuberculous mycobacteria in the sputum of HIV-infected patients: infection or colonization?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10983659" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Detection, identification, and treatment of a novel, non-cultivable Mycobacterium species in an HIV patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31167842" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32628747" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35090639" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15919622" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16231262" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18647877" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : First UK report of successful treatment of Mycobacterium simiae and immune reconstitution inflammatory syndrome in an HIV-seropositive patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33501968" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : To Induce Immune Reconstitution Inflammatory Syndrome or Suppress It: The Spectrum of Mycobacterium genavense in the Antiretroviral Era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2912355" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6815283" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Isolation of nontuberculous mycobacteria in the United States, 1980.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8783725" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Emergence of Mycobacterium kansasii as the leading mycobacterial pathogen isolated over a 20-year period at a midwestern Veterans Affairs hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9195089" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Mycobacterium kansasii disease in patients infected with human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10517196" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Mycobacterium kansasii infection in patients infected with the human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9841601" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12905144" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Epidemiological, clinical, and prognostic differences between the diseases caused by Mycobacterium kansasii and Mycobacterium tuberculosis in patients infected with human immunodeficiency virus: a multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8994523" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Pulmonary Mycobacterium kansasii infection: comparison of radiological appearances with pulmonary tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9790143" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Multiple cranial osteolytic lesions due to Mycobacterium kansasii in a patient with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15220694" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A systematic review of the clinical significance of pulmonary Mycobacterium kansasii isolates in HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15215152" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Mortality prediction in pulmonary Mycobacterium kansasii infection and human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17352101" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Mycobacterium kansasii in HIV patients: clarithromycin and antiretroviral effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9332511" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Mycobacterium xenopi infection in patients with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9279284" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9674460" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Clinical and radiographic manifestations of uncommon pulmonary nontuberculous mycobacterial disease in AIDS patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18325251" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Mycobacterium xenopi clinical relevance and determinants, the Netherlands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15750135" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Spondylitis due to Mycobacterium xenopi in a human immunodeficiency virus type 1-infected patient: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18193243" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Spondylodiscitis caused by Mycobacterium xenopi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8894345" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24841195" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Central nervous system infection due to Mycobacterium haemophilum in a patient with acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32226763" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Intramedullary spinal cord lesions in an immunocompromised host due to Mycobacterium haemophilum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1623075" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Varied presentations and responses to treatment of infections caused by Mycobacterium haemophilum in patients with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8256970" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Clinical and epidemiologic characteristics of Mycobacterium haemophilum, an emerging pathogen in immunocompromised patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28959701" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Disabling Dactylitis and Tenosynovitis Due to Mycobacterium haemophilum in a Patient With Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21700242" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Disseminated Mycobacterium haemophilum infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31441427" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Clinical Characteristics and Treatment Outcomes for Patients Infected with Mycobacterium haemophilum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8218698" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Mycobacterium simiae infection in Israeli patients with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11023758" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Disseminated Mycobacterium simiae infection in patients with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9730300" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Successful treatment of disseminated Mycobacterium simiae infection in AIDS patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33273186" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Successful treatment of disseminated Mycobacterium simiae infection in a patient with advanced HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8904448" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Mycobacterium malmoense bacteremia in two AIDS patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11488069" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Clinical and pathologic features of Mycobacterium fortuitum infections. An emerging pathogen in patients with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8357113" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12060872" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Pseudo-outbreak of Mycobacterium fortuitum on a Human Immunodeficiency Virus Ward: transient respiratory tract colonization from a contaminated ice machine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2288568" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Fatal infection with a novel, unidentified mycobacterium in a man with the acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9663512" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Mycobacterium genavense in AIDS patients, report of 24 cases in Italy and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21694645" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Mycobacterium genavense infections: a retrospective multicenter study in France, 1996-2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10565904" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Disseminated infection with Mycobacterium genavense: a challenge to physicians and mycobacteriologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24231409" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Mycobacterium genavense specific mesenteritic syndrome in HIV-infected patients: a new entity of retractile mesenteritis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11218013" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Mycobacterium genavense infection in AIDS: imaging findings in eight patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34788633" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : High overall mortality of Mycobacterium genavense infections and impact of antimycobacterial therapy: Systematic review and individual patient data meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29018644" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Mycobacterium Genavense Granuloma Mimicking a Brain Tumor: A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15764180" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Osteomyelitis and skin ulcers caused by Mycobacterium szulgai in an AIDS patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15849060" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Septic arthritis due to Mycobacterium szulgai in a patient with human immunodeficiency virus: case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17064210" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Mycobacterium szulgai in a patient with advanced acquired immunodeficiency syndrome: an unusual pathogen with unusual multidrug resistance.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
